These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 20040322)

  • 21. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy.
    Stroobants S; Gerlach D; Matthes F; Hartmann D; Fogh J; Gieselmann V; D'Hooge R; Matzner U
    Hum Mol Genet; 2011 Jul; 20(14):2760-9. PubMed ID: 21515587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysosomal storage diseases.
    Burlina AP; Manara R; Gueraldi D
    Handb Clin Neurol; 2024; 204():147-172. PubMed ID: 39322377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.
    Scarpa M; Bellettato CM; Lampe C; Begley DJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):159-71. PubMed ID: 25987170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
    Köse S; Aerts-Kaya F; Uçkan Çetinkaya D; Korkusuz P
    Adv Exp Med Biol; 2021; 1347():135-162. PubMed ID: 33977438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.
    Valayannopoulos V
    Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
    Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
    Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases.
    Gurda BL; Vite CH
    Hum Mol Genet; 2019 Oct; 28(R1):R119-R131. PubMed ID: 31384936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease.
    Hassiotis S; Beard H; Luck A; Trim PJ; King B; Snel MF; Hopwood JJ; Hemsley KM
    Eur J Neurosci; 2014 Jun; 39(12):2139-50. PubMed ID: 25068161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
    Mader KM; Beard H; King BM; Hopwood JJ
    Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic approaches for neuronopathic lysosomal storage disorders.
    Schiffmann R
    J Inherit Metab Dis; 2010 Aug; 33(4):373-9. PubMed ID: 20162366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
    Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
    Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
    Chang M; Cooper JD; Sleat DE; Cheng SH; Dodge JC; Passini MA; Lobel P; Davidson BL
    Mol Ther; 2008 Apr; 16(4):649-56. PubMed ID: 18362923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones.
    Wei H; Kim SJ; Zhang Z; Tsai PC; Wisniewski KE; Mukherjee AB
    Hum Mol Genet; 2008 Feb; 17(4):469-77. PubMed ID: 17989065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.